-
Featured News /
Cell Therapies Pty Ltd has become the first approved CAR-T commercial manufacturing site in Australia, providing potentially faster access to CAR-T therapies to eligible patients in the region with life-threatening blood cancers.
Novartis global commercial CAR-T manufacturing footprint now spans four continents, bringing these transformative therapies closer to patients and healthcare professionals around the world. -
Statement /
-
Story /New Global Head of Business Development and Licensing for research makes connections naturally, decisions scientifically.
-
Story / -
Story /NIBR investigator develops technology that uses tumor DNA in the blood for diagnostics
-
Story /Ice hockey used to help Tyler Patron combat cystic fibrosis, but he hopes the lab could yield stronger medicine.
-
Story /A Novartis team blazes new trails with an experimental treatment for spinal muscular atrophy.
-
Story /Ambitious scientist accelerates research into African genomic diversity and health challenges with internship
-
Story /Blocking an inflammatory pathway may offer a new way to treat autoimmune disease.
-
Story /Learn how Novartis is using technology to improve the oncology clinical trial process.